T(
AbelZeta Pharma Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Not Specified (Hematologic Malignancies) | Hematologic Malignancies | Clinical |
| Not Specified (Inflammatory & Immunological) | Inflammatory & Immunological Diseases | Clinical |
| Not Specified (Solid Tumors) | Solid Tumors | Clinical |
Leadership Team at AbelZeta Pharma
YY
Yihong Yao, Ph.D., BS
Chief Scientific Officer
AC
Andrew Chan, JD, MBA
Chief Legal Officer and Company Secretary
MH
Michael Havert, Ph.D.
Senior Vice President, Regulatory Affairs & Quality, US
JH
Jiaqi Huang, MD, Ph.D.
Senior Vice President, Translational Medicine
MM
Matt Mandel, MD
Senior Vice President, Clinical